SEC Comment Letter for ENZON PHARMACEUTICALS, INC. (ENZN) (CIK 0000727510) (VISK) — Aug 23, 2007

ENZON PHARMACEUTICALS, INC. (ENZN) (CIK 0000727510)
Date: Aug. 23, 2007 · CIK: 0000727510 · Accession: 0000000000-07-041244

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

August 23, 2007

Author

Not clearly detected

Form

UPLOAD

Company

ENZON PHARMACEUTICALS, INC. (ENZN) (CIK 0000727510)

Letter

Via Facsimile and U.S. Mail Mail Stop 6010 August 23, 2007 Mr. Craig A. Tooman Executive Vice President, Finance, and Chief Financial Officer Enzon Pharmaceuticals, Inc. 685 Route 202/206 Bridgewater, NJ 08807 Re: Enzon Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2006 Filed March 2, 2007 File No. 0-12957

Dear Mr. Tooman:

We have completed our review of your Form 10-K and have no further comments at this time. Sincerely, J o e l P a r k e r A c c o u n t i n g B r a n c h C h i e f

Show Raw Text

Via Facsimile and U.S. Mail Mail Stop 6010                                                                                                 August 23, 2007   Mr. Craig A. Tooman Executive Vice President,  Finance, and Chief Financial Officer Enzon Pharmaceuticals, Inc. 685 Route 202/206  Bridgewater, NJ  08807
Re: Enzon Pharmaceuticals, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2006 Filed March 2, 2007
 File No. 0-12957

Dear Mr. Tooman:

We have completed our review of your Form 10-K and have no further comments
at this time.
        Sincerely,            J o e l  P a r k e r          A c c o u n t i n g  B r a n c h  C h i e f

SecProbe.io